ResMed Not Getting Enough Credit for Cost Control -- Market Talk

Dow Jones

Jan 23, 2025

0243 GMT - Breathing-tech provider ResMed doesn't get enough credit from the market for its operational cost control, UBS analyst Laura Sutcliffe reckons. Dual-listed ResMed is scheduled to report its December-quarter financials at the end of January and Sutcliffe thinks its core operating profit will come in about 2% ahead of the average analyst forecast. This is even though her revenue forecast is in line with average expectations. As for U.S. device sales, she tells clients in a note that app downloads suggest that its market share remains steady above 80%. UBS raises its target price on ResMed's U.S.-listed securities by 2% to US$255.00. The stock closed 0.2% lower at US$247.33. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

January 22, 2025 21:43 ET (02:43 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2505035327"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2505035327\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2505035327?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-23 10:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505035327","market":"other","top_or_hot":-1,"title":"ResMed Not Getting Enough Credit for Cost Control -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0243 GMT - Breathing-tech provider ResMed doesn't get enough credit from the market for its operational cost control, UBS analyst Laura Sutcliffe reckons. Dual-listed ResMed is scheduled to report its December-quarter financials at the end of January and Sutcliffe thinks its core operating profit will come in about 2% ahead of the average analyst forecast. This is even though her revenue forecast is in line with average expectations. As for U.S. device sales, she tells clients in a note that app downloads suggest that its market share remains steady above 80%. UBS raises its target price on ResMed's U.S.-listed securities by 2% to US$255.00. The stock closed 0.2% lower at US$247.33. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 22, 2025 21:43 ET (02:43 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ResMed Not Getting Enough Credit for Cost Control -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nResMed Not Getting Enough Credit for Cost Control -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-23 10:43</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0243 GMT - Breathing-tech provider ResMed doesn't get enough credit from the market for its operational cost control, UBS analyst Laura Sutcliffe reckons. Dual-listed ResMed is scheduled to report its December-quarter financials at the end of January and Sutcliffe thinks its core operating profit will come in about 2% ahead of the average analyst forecast. This is even though her revenue forecast is in line with average expectations. As for U.S. device sales, she tells clients in a note that app downloads suggest that its market share remains steady above 80%. UBS raises its target price on ResMed's U.S.-listed securities by 2% to US$255.00. The stock closed 0.2% lower at US$247.33. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 22, 2025 21:43 ET (02:43 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4567","symbol_name":"ESG概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2505035327","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505035327","pubTimestamp":1737600180,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0243 GMT - Breathing-tech provider ResMed doesn't get enough credit from the market for its operational cost control, UBS analyst Laura Sutcliffe reckons. Dual-listed ResMed is scheduled to report its December-quarter financials at the end of January and Sutcliffe thinks its core operating profit will come in about 2% ahead of the average analyst forecast. This is even though her revenue forecast is in line with average expectations. As for U.S. device sales, she tells clients in a note that app downloads suggest that its market share remains steady above 80%. UBS raises its target price on ResMed's U.S.-listed securities by 2% to US$255.00. The stock closed 0.2% lower at US$247.33. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4567":"ESG概念","BK4588":"碎股","BK4548":"巴美列捷福持仓","BK7501":"新冠治疗股","BK4585":"ETF&股票定投概念","BK4082":"医疗保健设备","RMD.AU":"Resmed DRC","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","BK4504":"桥水持仓","BK7007":"医疗保健设备","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","RMD":"瑞思迈"},"translate_title":"瑞思迈在成本控制方面没有获得足够的信任——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RMD.AU":0.9,"RMD":1},"content_text":"0243 GMT - Breathing-tech provider ResMed doesn't get enough credit from the market for its operational cost control, UBS analyst Laura Sutcliffe reckons. Dual-listed ResMed is scheduled to report its December-quarter financials at the end of January and Sutcliffe thinks its core operating profit will come in about 2% ahead of the average analyst forecast. This is even though her revenue forecast is in line with average expectations. As for U.S. device sales, she tells clients in a note that app downloads suggest that its market share remains steady above 80%. UBS raises its target price on ResMed's U.S.-listed securities by 2% to US$255.00. The stock closed 0.2% lower at US$247.33. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 22, 2025 21:43 ET (02:43 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}